期刊文献+

Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM

Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
下载PDF
导出
摘要 In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments. In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.
作者 Fan Yang Xiaoping Tan Fan Yang;Xiaoping Tan(Department of Gastrosenterology, First Hospital of Yangtze University, Jingzhou, China;Digestive Disease Research Institution of Yangtze University, Jingzhou, China;Clinical Medical College, Yangtze University, Jingzhou, China)
出处 《Journal of Biosciences and Medicines》 2024年第1期115-125,共11页 生物科学与医学(英文)
关键词 Sodium-Glucose Cotransporter-2 Inhibitors Non-Alcoholic Fatty Liver Disease Diabetes Mellitus Sodium-Glucose Cotransporter-2 Inhibitors Non-Alcoholic Fatty Liver Disease Diabetes Mellitus
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部